MX2024011716A - Formulacion de x842 - Google Patents

Formulacion de x842

Info

Publication number
MX2024011716A
MX2024011716A MX2024011716A MX2024011716A MX2024011716A MX 2024011716 A MX2024011716 A MX 2024011716A MX 2024011716 A MX2024011716 A MX 2024011716A MX 2024011716 A MX2024011716 A MX 2024011716A MX 2024011716 A MX2024011716 A MX 2024011716A
Authority
MX
Mexico
Prior art keywords
formulation
amorphous
present disclosure
water
oral administration
Prior art date
Application number
MX2024011716A
Other languages
English (en)
Spanish (es)
Inventor
Jianxin Wang
Jiangang Yang
Pingsheng Hu
Ming Lu
Original Assignee
Guizhou Sinorda Biomedicine Co Ltd
Shanghai Sinorda Biomedicine Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Guizhou Sinorda Biomedicine Co Ltd, Shanghai Sinorda Biomedicine Co Ltd filed Critical Guizhou Sinorda Biomedicine Co Ltd
Publication of MX2024011716A publication Critical patent/MX2024011716A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2024011716A 2022-03-30 2024-09-24 Formulacion de x842 MX2024011716A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/CN2022/084214 WO2023184282A1 (en) 2022-03-30 2022-03-30 X842 formulation
PCT/CN2023/083375 WO2023185624A1 (en) 2022-03-30 2023-03-23 X842 formulation

Publications (1)

Publication Number Publication Date
MX2024011716A true MX2024011716A (es) 2024-11-08

Family

ID=81386826

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024011716A MX2024011716A (es) 2022-03-30 2024-09-24 Formulacion de x842

Country Status (8)

Country Link
US (1) US20260166014A1 (enExample)
EP (1) EP4499046A1 (enExample)
JP (1) JP2025511145A (enExample)
KR (1) KR20240165457A (enExample)
CN (2) CN119139298A (enExample)
AU (1) AU2023247528A1 (enExample)
MX (1) MX2024011716A (enExample)
WO (2) WO2023184282A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024230943A1 (en) * 2023-05-08 2024-11-14 Cinclus Pharma Holding AB (publ) Linaprazan glurate for treating gastroesophageal reflux disease (gerd)
WO2026032974A1 (en) 2024-08-05 2026-02-12 Cinclus Pharma Holding AB (publ) Formulation of linaprazan glurate

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1368006B1 (en) * 2001-02-13 2006-05-03 AstraZeneca AB Novel modified released formulation
US20050249799A1 (en) * 2004-03-03 2005-11-10 Spherics, Inc. Polymeric drug delivery system for hydrophobic drugs
CN101513403A (zh) * 2008-02-21 2009-08-26 上海慧德医药科技有限公司 含有苯并咪唑类化合物的药物制剂
FI20086158A0 (fi) 2008-12-03 2008-12-03 Mikael Dahlstroem Imidatsopyridiinijohdannaiset
CN103301066B (zh) * 2012-03-15 2018-12-07 苏州泽璟生物制药有限公司 一种改善吸收性能的固体分散体及其制备
CN106279151A (zh) * 2015-06-26 2017-01-04 江苏太瑞生诺生物医药科技有限公司 5-(2-(8-((2,6-二甲基苄基)氨基)-2,3-二甲基咪唑并[1,2-a]吡啶-6-甲酰胺基)乙氧基)-5-氧代戊酸的固体形式及其制备方法
US20210330599A1 (en) * 2016-08-01 2021-10-28 University Of Rochester Nanoparticles for Controlled Release of Anti-Biofilm Agents and Methods of Use
WO2020101860A1 (en) 2018-11-16 2020-05-22 Cnh Industrial America Llc System and method for aligning arms of an agricultural header
EP4054537B1 (en) * 2019-11-04 2023-06-07 Cinclus Pharma Holding AB (publ) Oral formulation of x842
WO2021152623A1 (en) * 2020-01-27 2021-08-05 Dr. Reddy’S Laboratories Limited Improved processes for the preparation of tafamidis and its meglumine salt
US20220002297A1 (en) 2020-07-02 2022-01-06 Cinclus Pharma Ag Polymorphs of x842

Also Published As

Publication number Publication date
WO2023184282A1 (en) 2023-10-05
AU2023247528A1 (en) 2024-09-26
US20260166014A1 (en) 2026-06-18
CN119139298A (zh) 2024-12-17
KR20240165457A (ko) 2024-11-22
CN117157059B (zh) 2024-09-13
WO2023185624A1 (en) 2023-10-05
CN117157059A (zh) 2023-12-01
EP4499046A1 (en) 2025-02-05
JP2025511145A (ja) 2025-04-15

Similar Documents

Publication Publication Date Title
UY27908A1 (es) Formulaciones y formas de dosificación para la administración controlada de topiramato
CO2021005774A2 (es) Lípidos con amina ionizables
CR7362A (es) Formulaciones farmaceuticas de derivado de platino
MX2019012447A (es) Sistemas de administracion de liberacion sostenida que comprenden ligantes que no dejan huellas.
AR039744A1 (es) Metodos y formas de dosificacion para aumentar la solubilidad de las composiciones de farmacos para la administracion controlada
CO2019001895A2 (es) Formulación novedosa para administración por vía oral
NZ594618A (en) Transdermal pharmaceutical preparations
UY39192A (es) Dispersión sólida, proceso para prepararla y forma de dosificación farmacéutica suministrable por vía oral que la comprende
AR004391A1 (es) Formulacion de liberacion controlada para farmacos basicos escasamente solubles.
PA8526101A1 (es) Formulaciones de liberacion sostenida para secretagogos de hormona del crecimiento
AR065809A1 (es) Formulaciones farmaceuticas que contienen un inhibidor sglt2
AR034813A1 (es) Composiciones farmaceuticas y uso de las mismas
MX2023003369A (es) Formulacion farmaceutica de liberacion prolongada.
MX2024004488A (es) Formulaciones y sistemas de erdafitinib para administración intravesical.
UY29701A1 (es) Formulaciones líquidas para la administración controlada de derivados de bencisoxazol
EP4356968A3 (en) Long-acting formulations
MY208261A (en) Oral pharmaceutical composition
MX2023003097A (es) Composiciones farmaceuticas que comprenden un oligonucleotido antisentido para administracion oral.
AR046402A1 (es) Combinacion de principio activo que comprende un compuesto 2,5-dihidrobencenosulfonico y un modulador de los canales de potasio
CO2025018537A2 (es) Formulación que comprende un conjugado anticuerpo-fármaco dirigido a claudina 18.2, método para su preparación y uso
MX2020010400A (es) Formulacion de goma oral y proceso de preparacion de la misma.
CL2024003979A1 (es) Composición farmacéutica que comprende un inhibidor de endonucleasa dependiente de cap.
CL2025000209A1 (es) Formulación farmacéutica estable líquida oral de un agente antiespasmódico
BR112023003572A2 (pt) Formulação oral sólida de utidelona
AR103466A1 (es) Formulación galenica que comprende un fármaco tópico